Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 300Neoplasms 297Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Prostatic Neoplasms 149Recurrence 147Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 130Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 114Advanced Solid Tumor 109Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Interventions

eribulin 1Paclitaxel 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × HER2-low Breast Cancer × Clear all
NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡